Regeneron Q2 2019收入超过估计,导致分析师的多重价格目标增加。 Regeneron Q2 2019 earnings exceeded estimates, leading to multiple price target increases from analysts.
Regenenron制药公司(NASDAQ:REGN)从各种分析家那里收到了多种价格目标的增加,包括加拿大皇家银行(1 240美元)、巴克莱公司(1 220美元)、坎托尔·菲茨杰拉尔德公司(1 000美元)和特鲁斯特金融公司(1 200美元)。 Regeneron Pharmaceuticals (NASDAQ: REGN) has received multiple price target increases from various analysts, including Royal Bank of Canada ($1,240), Barclays ($1,220), Cantor Fitzgerald ($1,000), and Truist Financial ($1,200). 该公司报告,Q2 2019收入为11.56 EPS, 超过分析师的估计数263美元,对中价购买的评分一致,平均价格目标为1 097.05美元。 The company reported Q2 2019 earnings of $11.56 EPS, exceeding analysts' estimates by $2.63, and has a consensus rating of Moderate Buy and an average price target of $1,097.05. Regeneron的季度收入比上一年增加了12.3%。 Regeneron's quarterly revenue increased by 12.3% compared to the previous year.